550 South Winchester Boulevard
88 articles with SI-BONE, Inc.
SI-BONE Announces Medicare Physician Payment Increase of 27% for Minimally Invasive SI Joint FusionNew Payment Rates Based on Increased RVUs to Reflect More Appropriate Compensation for Surgeons
SI-BONE, Inc. announced the Centers for Medicare and Medicaid Services has updated the Medicare Physician Fee Schedule for CPT® Code 27279, used to report minimally invasive sacroiliac joint fusion procedures, which are commonly performed with the iFuse Implant System®.
SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced it will report financial results for the third quarter of 2019 after market close on Monday, November 11, 2019.
PrinterPrezz to Work With SI-BONE to Speed Innovation in Metal 3D Printed Orthopedic Medical Devices
PrinterPrezz, Inc. announced that it has signed a customer agreement with SI-BONE, Inc., a medical device company that pioneered the minimally invasive surgical treatment of the sacroiliac joint with the iFuse Implant System®.
The Nasdaq indicated that there was a record amount of biotech initial public offerings this year, including some individual record-breakers—Moderna, Allogene Therapeutics and Rubius Therapeutics. The total for the year is around $8.2 billion raised, breaking 2014’s record of $6.5 billion.
SI-BONE, Inc. (Nasdaq: SIBN), a medical device company that is pioneering the minimally invasive surgical treatment of the sacroiliac joint with the iFuse Implant System®, today announced it will report financial results for the third quarter of 2018 after market close on Thursday, November 29, 2018.
A summary of IPOs from companies in the biotech and pharma world since Oct. 1, 2018.
10/31/2018October was a busy month as multiple biopharma companies made their debut as publicly traded entities and even more companies filed their intentions to go public with an initial public offering. BioSpace takes a look back at some of the key IPOs of the month.
SI-BONE Announces Closing of Initial Public Offering and Exercise in Full of Underwriters' Option to Purchase Additional Shares
SI-BONE, Inc. (Nasdaq: SIBN) ("SI-BONE"), a medical device company that pioneered the minimally invasive surgical treatment of the sacroiliac joint with the iFuse Implant System®, today announced the closing of its initial public offering of 8,280,000 shares of common stock, at a price to the public of $15.00 per share,
SI-BONE, Inc. today announced the pricing of its initial public offering of 7,200,000 shares of common stock at a price to the public of $15.00 per share.
SI-BONE, Inc. Announces that NICE, the UK National Institute for Health and Care Excellence, Published Medical Technology Guidance Finding that the Evidence Supports Treatment of Sacroiliac Joint Pain with the iFuse Implant System®
The recommendation, unique to iFuse among sacroiliac joint fusion devices, concludes that using iFuse leads to improved pain relief, better quality of life and less disability compared to non-surgical management
SI-BONE, Inc. today announced that it has publicly filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission ("SEC") relating to a proposed initial public offering of shares of its common stock.
SI-BONE, Inc. Announces France's National Healthcare System Establishes Exclusive Positive Coverage for the Triangular iFuse Implant System® for MIS SI Joint Fusion
Exclusive Coverage Based on Published Clinical Evidence Begins September 6, 2018 and Extends for 5 Years
SI-BONE, Inc. Hosts ISASS 2018 Sacroiliac Joint Workshop led by David Polly, MD, Bengt Sturesson, MD, Peter Whang, MD and Brad Duhon, MD
Eight Podium Presentations will focus on the SI Joint, including a one-hour SI Joint Symposium moderated by Frank Phillips, MD and Morgan Lorion, MD
SI-BONE, Inc. Announces Publication of 3-Year Long-term Prospective Outcomes Including Randomized Controlled Trial Data on 103 Patients Post SI Joint Fusion with Triangular iFuse Implant System®
Results include 57 Patients at 4 years showing continued durability
SI-BONE Announces Blue Cross Blue Shield Association Raises Clinical Evidence Rating for MIS SI Joint Fusion
SI-BONE announced that BCBSA, after an extensive review of all existing peer-reviewed published clinical safety and effectiveness data, has assigned triangular implants for SI joint fusion a "Moderate" quality evidence recommendation.
SI-BONE's New iFuse-Navigation Set and iFuse-3D Fenestrated SI Joint Fusion Implant to be Featured at the 2017 North American Spine Society Annual Meeting
SI-BONE announced its new iFuse-Navigation Set and proprietary 3D printed iFuse-3D fenestrated triangular titanium implant, will be featured at this year's North American Spine Society (NASS) annual meeting in Orlando, FL.
SI-BONE Announces Utah's Public Employees Health Plan (PEHP) Establishes Coverage For The Ifuse Procedure For Minimally Invasive SI Joint Fusion
SI-BONE Announces Publication Of Imia - A 2nd Multicenter Randomized Controlled Trial Of The IFuse Implant System Vs Conservative Care
SI-BONE Announces Highmark, Inc., 4th Largest Blue Cross Blue Shield Plan And 10th Largest U.S. Commercial Payor, Establishes Positive Coverage Policy For Minimally Invasive Sacroiliac Joint Fusion Exclusively For The iFuse Implant System
SI-BONE Announces Publication Of A Level I Study Demonstrating Strong Clinical Prediction For The Diagnosis Of SI Joint Dysfunction